Targeted drug with radiation for advanced EGFR-positive cancers
Treatments studied
Part of Cancer clinical trials.
This trial tests a new targeted drug (cetuximab β) combined with radiation and chemotherapy for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- Your cancer is advanced (has spread or come back) and no standard treatment has worked or you can't tolerate standard treatment.
- Your tumor tests positive for a protein called EGFR (a lab test on a biopsy). If your tumor is colorectal cancer, it needs to be RAS/BRAF wild-type (a specific genetic type).
- You have at least one tumor that can be measured on a scan (larger than 1 cm).
- You are able to care for yourself (a score of 0-3 on a daily activity scale) and expected to live at least 3 months.
- You do not have serious problems with your blood, heart, lungs, liver, or kidneys, and no active infections or immune system issues.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding radiation therapy to a drug combination can help people with a specific type of lung cancer that has stopped responding to standard first-line pills. It's for patients whose cancer has a certain gene change (EGFR) and has spread to other parts of the body.
This trial tests a combination of two targeted drugs (cetuximab beta and fruquintinib) with or without an immunotherapy drug for people with a specific type of advanced colorectal cancer that has not been treated before. It aims to see if this approach is safe and effective for those whose tumors have certain genetic markers (RAS and BRAF wild type).
This study tests a combination of two medications—cetuximab (a targeted antibody) and either pembrolizumab or finotonlimab (immunotherapies)—along with chemotherapy, for advanced head and neck cancer that has spread or come back. The goal is to see if this combination helps shrink tumors and improve survival compared to standard treatment.
This trial tests whether anti-EGFR therapy works better for people with left-sided colorectal cancer that has spread, whose tumors do not have certain gene mutations (RAS wild-type). It is for those who have not yet had treatment for metastatic disease.
This study tests a new targeted drug (MRG003) combined with precise radiation (SBRT) for people with EGFR-positive solid tumors that have spread to a few new spots. The goal is to see if this combination works better than standard treatments to control the cancer.
This trial tests whether adding focused radiation therapy to the spots of cancer that remain after your first treatment (an EGFR pill plus chemo) can help control advanced lung cancer better. It is for people whose cancer has an EGFR mutation and who have only a few residual spots, with the goal of delaying progression and improving outcomes.
Hear when a new Advanced Refractory Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.